Estimated 10-year cardiovascular risk in a British population: Results of a national screening project

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1322-1331

  Neil, H A W ^a   Perera, R ^a   Armitage, J M ^a   Farmer, A J ^a   Mant, D ^a   Durrington, P N ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 49349114195     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01828.x     Document Type: Article

References (35)

1. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366: 1267 78.
2. Heart Protection Study Collaborative Group. Lifetime cost-effectiveness of simvastatin in a wide range of risk and age groups derived from a randomised trial of 20 536 individuals. BMJ 2006 333: 1145 8.
3. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000, http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094275 (accessed April 2008).
4. Wood D, Wray R, Poulter N et al. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 92 (Suppl. V): v1 52.
5. National Institute of Health and Clinical Excellence. Statins for the Prevention of Cardiovascular Disease Events in Patients at Increased Risk of Developing Cardiovascular Disease or Those With Established Cardiovascular Disease. Technology Appraisal 94. London: NICE, 2006, http://www.nice.org.uk/ TA094 (accessed April 2008).
6. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003 24: 1601 10.
7. National Cholesterol Education Program. Recommendations on Lipoprotein Measurement From the Working Group on Lipoprotein Measurement. NIH Pub. No.95-3044. Bethesda, MD: National Heart, Lung and Blood Institute, 1994: 186.
8. Rogers EJ, Misner L, Ockene IS, Nicolosi RJ. Evaluation of seven Cholestech LDX analyzers for total cholesterol. Clin Chem 1993 39: 860 4.
9. Cobbaert C, Boerma GJM, Lindemans J. Evaluation of the Cholestech LDX analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. Eur J Clin Chem Clin Biochem 1994 32: 391 4.
10. Batki AD, Holder R, Thomason HL, Thorpe GHG. Evaluation Report: Cholestech LDX Analyser. Medical Devices Agency, London, 1995.
11. Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random population. BMJ 1995 311: 1401 5.
12. Cuckson AC, Reinders A, Shabeeh H, Shennan AH. Validation of the Microlife BP 3BTO-A oscillometric blood pressure monitoring device according to a modified British Hypertension Society protocol. Blood Press Monit 2002 7: 319 24.
13. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Human Hypertens 2004 18: 139 85.
14. Anderson KM, Odell PM, Wilson PWF, Kanell WB. Cardiovascular disease risk profiles. Am Heart J 1991 121: 293 8.
15. Simvastatin over the counter. Drug Ther Bull 2005 43: 25 8.
16. Office for National Statistics. Mid-2004 Population estimates for UK, England and Wales, Scotland and Northern Ireland. http://www.statistics.gov.uk/ statbase/Product.asp?vink=15106 (accessed September 2006).
17. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285: 2486 97.
18. Department of Health. Health Survey for England. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsStatistics/DH_4098712 (accessed June 2008).
19. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008 94: 34 9.
20. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007 335: 136 41. doi:.
21. Cooper A, Nherera L, Robson J et al. Clinical Guidelines and Evidence Review for Cardiovascular risk assessment: the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. Section 4.3: appendix; pp 32 43 (Consultation). London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008. http://www.nice.org.uk/nicemedia/pdf/LipidModConsSection4.pdf (accessed April 2008).
22. Peto R. Doubts about QRISK Score: Total/HDL Cholesterol should be Important. http://www.bmj.com/cgi/letters/1335/7611/136 (accessed July 2007).
23. British Heart Foundation and European Heart Network. European Cardiovascular Statistics, 3rd edn. London: British Heart Foundation, 2008. http://www.heartstats.org/datapage.asp?id=7683 (accessed June 2008).
24. Marshal T. When measurements are misleading: modelling the effects of blood pressure misclassification in the English population. BMJ 2004 328: 933.
25. Pickering TG. Blood pressure measurement and the detection of hypertension. Lancet 1994 344: 31 5.
26. Bland JM, Altman DG. Statistics Notes: Regression towards the mean. BMJ 1994 308: 1499.
27. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk assessment in patients without diabetes. J Cardiovasc Risk 2002 9: 183 90.
28. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 326: 1419 24.
29. Department of Health. Putting Prevention First: vascular checks: risk assessment and management. http://www.dh.gov.uk/en/Publicationsandstatistics/ PublicationsPolicyAndGuidance/DH_083822.
30. Mcelduff P, Jaefarnezhad M, Durrington PN. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart 2006 92: 1213 8.
31. Sever P, Dahlof B, Poulter N et al. on behalf of the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006 27: 2982 8.
32. Phillips AN, Goya S, Wannamethee SG, Walker M, Thomason A, Smith GD. Life Expectancy in men who have never smoked and those who have smoked continuously: 15 year follow up of large cohort of middle aged British men. BMJ 1996 313: 907 8.
33. Vartianinen E, Puska P, Pekkanen J, Toumilehto J, Jousiahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994 309: 23 7.
34. Neil HAW, Hawkins MM. Durrinton PN, Betteridge DJ, Capps NE, Humphries SE for the Simon Broome Familial Hyperlipidaemia Register and Scientific Steering Committee. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia. Atherosclerosis 2005 179: 293 7.
35. London Health Observatory. A Briefing on Inequalities in Life Expectancy and Deaths From Cancers, Heart Disease and Stroke in London. http://www.lho.org.uk/ViewResources.aspx?id=11106 (accessed June 2008).